CRISPR (CRSP) Rated Overweight on Gene Editing Growth
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years.
Crispr Therapeutics Ag (CRSP)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bourgeon Capital John Zaro | 5,600 | $266,392 | 0.05% | |
| 2. | Hurley Capital Charles Goldblum | 80 | $3,806 | 0% | |
| 3. | 0 | $0 | 0% | ||
| 4. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.96 | 1,508 | $49,703.68 | 1,508 | 2025-04-03 | Filing | |
| $57.03 | 20,000 | $1,140,600.00 | 22,000 | 2025-08-06 | Filing | |
| $52.03 | 960,983 | $49,999,945.49 | 1,730,179 | 2025-07-16 | Filing | |
| $52.03 | 22,319 | $1,161,257.57 | 238,897 | 2025-07-16 | Filing | |
| $52.03 | 6,510 | $338,715.30 | 69,687 | 2025-07-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.78 | 3,182 | $148,853.96 | 94,308 | 2026-03-23 | Filing | |
| $46.78 | 10,020 | $468,735.60 | 255,501 | 2026-03-23 | Filing | |
| $46.78 | 3,708 | $173,460.24 | 15,565 | 2026-03-23 | Filing | |
| $48.26 | 3,150 | $152,019.00 | 13,143 | 2026-03-16 | Filing | |
| $48.26 | 4,021 | $194,053.46 | 13,773 | 2026-03-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,853,875 | $88,188,834 | 1.25% | |
| 2. | 1,853,875 | $88,188,834 | 0.06% | |
| 3. | 1,762,530 | $83,843,552 | 0.01% | |
| 4. | 1,142,543 | $54,350,771 | 0% | |
| 5. | 546,826 | $26,012,513 | 0% |
News See All
10 Stocks That Could 10X Over the Next 10 Years
The last few years have been incredible for stock investors, with the S&P 500 returning 86% between 2023 and 2025.
Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now?
Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.
Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy
Ark Invest CEO Cathie Wood quickly became a Wall Street favorite back in the pandemic days with her disruptive investing and impressive returns.
CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth
CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years.
Long-Term Stock Portfolio: 15 Best Stocks for 20 Years
On March 9, Mohamed El-Erian, The Wharton School Rene Kern Professor & Allianz Chief Economic Advisor, joined 'Squawk Box' on CNBC to discuss the latest market trends, the impact of the Iran war, and ...
Here is Why CRISPR Therapeutics (CRSP) Appears so Good
The firm updated its estimates for CRISPR Therapeutics AG (NASDAQ:CRSP) and evaluated additional pipeline advancements after its partner Vertex Pharmaceuticals (VRTX) disclosed fourth-quarter sales data...
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street
Earlier on February 17, Chardan Capital lifted its price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $76 from $74 and maintained a Buy rating.
ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026
ARK Investment Management LLC, or ARK Invest, is an American investment management firm that oversees several actively managed ETFs.
Hedge Fund Resource Center